Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

By B. Zinman, C. Wanner, J. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O. Johansen, H. Woerle and 2 more. New England Journal of Medicine, 2015

5,975 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/b43c548120609d766a5fec5a495baa81903ab3f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. M. Husain
2. Christopher B. Newgard

Citations in the corpus

• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, neutral): “SUSTAIN-6 (subcutaneous semaglutide) [100], 2: PIONEER-6 (oral semaglutide) [101], 3: natide) [97], 6: ELIXA (lixisenatide) [95], 7: EMPA-REG Outcomes (empagliflozin) [120], 8: VERTIS-CV (ertugliflozin, presented at the 80th scientific session of the American Diabet SAVOR-TIMI-53 (saxagliptin) [125]”